Moderna price target raised to $45 from $35 at Bernstein

Bernstein raised the firm’s price target on Moderna (MRNA) to $45 from $35 and keeps a Market Perform rating on the shares following quarterly results. Despite the whiplash of FDA RTF last week for mRNA-1010, the stock held up well, the firm notes, recognition that a highly shorted stock with less-bad news on the horizon is enough of a catalyst.